Cost-effectiveness of targeted treatment vs chemoimmunotherapy in treatment-naive unfit CLL without TP53 aberrations
Autor: | Slot, Matilde, Niemann, Carsten Utoft, Ehlers, Lars Holger, Rotbain, Emelie Curovic |
---|---|
Zdroj: | In Blood Advances 8 August 2023 7(15):4186-4196 |
Databáze: | ScienceDirect |
Externí odkaz: |